Irvine,  CA 
United States
  • Booth: 3155

HEPATIQ, the ultimate liver test for predicting outcomes.

HEPATIQ calculates the PHM™ index of liver disease severity.  PHM™ has been proven to be an accurate predictor of clinical outcomes in the prospective seven year multi-center HALT-C trial of 1056 patients and A2ALL study for regeneration of liver function after an adult-to-adult liver donor liver transplant.
HEPATIQ has been cleared by the FDA for sale.
Dipu Ghosh, MSEE, MBA, CEO, dghosh@hepatiq.com
John Hoefs, MD, COO, jhoefs@hepatiq.com


Brands: HEPATIQ automatically analyses nuclear medicine liver images to calculate PHM. Patients with high-risk PHM have a 15-fold increase in risk for hepatic decompensation or liver-related death.

Do you have questions about getting the most from your eBooth? Check the eBooth FAQ.